Osimertinib approval date?

In the U.S., the FDA approved osimertinib (Tagrisso) on November 13, 2015, for metastatic EGFR T790M mutation-positive NSCLC after progression on EGFR-TKI therapy. If you need the approval date for a different country or for a different indication (e.g., first-line use), tell me which one and I’ll provide that.